RE:Investors in biotechs are a greedy bunchIf in 6 months 1) cancer is a nothingburger, 2) there are no new analysts or investor engagement does not change, and 3) the price is at or below current levels I can imagine seeing headlines of "TH management facing shreholder revolt" or "TH shareholders axe # board members in company shakeup". I would like to think Paul knows this and is making the nessesary changes, but Dubuc is still hanging around, so who knows...
palinc2000 wrote: and far from being risk adversed,,,Paul has or had an excellent reputation prior to joinung THTX
Paul s comment as being EXTREMELY EXCITED about Phase 1 should have been a SP booster .....
Yet Nothing changed after Pauls comments...No upgrades on oncology no new oncology analysts
I cant believe that cancer experts hired by investment firms have not been shown THTX material.
Paul will be judged harshly if Pase 1 turns out to be a nothingburgerI.had high hope after his comment but now hope has diminished and very little expectations,,However I am still high on Nash and revenues of legacy drugs